An exploratory trial of betaine supplementation in patients with schizophrenia - An exploratory trial of betaine supplementation in patients with schizophrenia

Department of Neuropsychiatry, The University of Tokyo Hospital0 个研究点目标入组 15 人开始时间: 2015年6月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) History of allergy to drugs 2) History of substance use disorder 3) High risk of suicide or other-injuring behavior 4) No agreement with contraception during participation of this study 5) Comorbidity or history of serious physical diseases 6) Organic brain disorder requiring treatment 7) Infection with HIV or hepatitis virus 8) Serious abnormality of vital sign, laboratory data, or electrocardiogram 9) Involuntarily hospital admission 10) Restriction of behavior 11) No disease notification 12) Electroconvulsive therapy or transcranial magnetic stimulation within 3 months before participation of this study 13) History of betaine use 14) Use of investigational drug within 3 months before participation of this study 15) More than 500 micromol/L of plasma methionine level 16) Doctor's decision

发起方

Department of Neuropsychiatry, The University of Tokyo Hospital